Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Share News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Avation extends easyJet lease; Abingdon wins deal

Mon, 06th Jun 2022 15:44

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Avation PLC - Singapore-based passenger aircraft leasing company - Agrees a 44-month lease term extension on an Airbus A320-200 aircraft operated by easyJet PLC, with the expiry date for the lease extended to October 2026 from March 2023.

----------

Abingdon Health PLC - lateral flow test developer and manufacturer - Signs deal to supply Taiwanese Arise Corp with 10 million Covid-19 antigen tests. "Abingdon will be launching, in calendar Q3 2022, a new e-commerce site, which will feature a range of lateral flow self-tests and professional-use tests under the Abingdon Simply Test brand. The Covid-19 test is one of these Abingdon Simply Tests," company adds.

----------

NetScientific PLC - London-based life sciences and sustainability technology investment firm - Portfolio firm PDS Biotechnology Corp granted US fast track designation for PDS0101 to be used in tandem with Merck & Co's Keytruda to treat recurrent or metastatic HPV16-positive head and neck cancer. The regulatory boost was awarded by the Food & Drug Administration.

----------

Renalytix PLC - London-based diagnostics company focused on kidney health - Says KidneyIntelX product successfully risk-stratified adult sufferers of type 2 diabetes and early-stage chronic kidney disease for outcomes including hospitalisation, heart failure and death.

----------

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says results from phase II clinical trial for Dementia treatment CogniCann show the product inhibits deterioration of behaviour in Dementia patients. This includes aggressive behaviour and agitation.

----------

Blencowe Resources PLC - miner focused on developing the Orom-Cross graphite project and Akelikongo nickel project in Uganda - Says final stage five metallurgical test results at Orom-Cross graphite project highlight quality of end product. "Over the coming months, additional post processing work for new potential applications for Orom-Cross graphite products will be completed. This work will support the progressive sales and marketing strategy focusing on both traditional and advanced graphite applications including both Primary and Secondary Battery Markets where is it expected the demand ahead for qualified graphite products will continue to expand and grow," Blencowe adds.

----------

Vaalco Energy Inc - Houston, Texas-based hydrocarbon exploration company - Drills South Tchibala 1HB-ST well in offshore Gabon. Discovers "significant columns of multiple hydrocarbon bearing sands" at Dentale interval. "With the drilling of the South Tchibala 1HB-ST well and completion in the Deep Dentale interval, Vaalco will add new reserves and production that were not previously in our 2P reserve base," Chief Executive Officer George Maxwell says.

----------

Oilex Ltd - Perth-based developer of natural gas assets - Says Cambay production in May averages 240,000 standard cubic feet per day of gas. "The majority of the production has been from the C-73 well but production from the C-77H well has been intermittently co-mingled to provide a route to higher production levels," Oilex says. Explains low pressure grid constraints have limited output rates to current roughly 300,000 scfd level. "The low pressure grid constraints are being addressed by the grid operator which will allow for higher production rates from the field," Oilex adds. "All major service and equipment have been secured for the planned C-77H re-frac operation. Currently, the workover rig is scheduled to be mobilised mid-June 2022 in order to prepare the C-77H well for fraccing operations, scheduled for mid-July 2022."

----------

Kropz PLC - African phosphate developer - Receives South African Reserve Bank approval for ZAR177 million, about GBP9.2 million, convertible equity facility from major Kropz shareholder ARC Fund. Says first ZAR103.5 million drawdown made last week Thursday.

----------

Coro Energy PLC - London-based gas explorer - Says production at Sillaro field recommences successfully after temporary suspension following a period of unexpectedly hot weather which caused more moisture to be produced. Coro adds: "Changes to the operation of the gas processing facility including the gas stripping rate for glycol regeneration, have seen significant improvements relating to the moisture in the sales gas bringing it well within the specifications required by the pipeline operator."

----------

Focusrite PLC - High Wycombe, Buckinghamshire-based music and audio products company - Launches Vocaster, an audio tools range of podcasters and other content creators. "The Vocaster range, starting at GBP189, is comprised of two standalone interfaces, Vocaster One and Vocaster Two, and two studio packs, Vocaster One Studio and Vocaster Two Studio. While Vocaster One is designed for the solo podcaster, Vocaster Two is designed for more dynamic shows that feature two hosts and/or audio segments. The studio packs contain Focusrite branded headphones and microphones, enabling users to begin recording high quality podcasts quickly and easily," Focusrite says.

----------

Schroder UK Public Private Trust PLC - London-based investment company focused on UK companies - Says investee Rutherford Health PLC has taken steps to wind-up company and appoint official receiver. The trust's holding in the oncology services provider was valued at GBP22.8 million on March 31. Due to uncertainty of outcome of proceedings, Schroder UK Public Private writes off the value of its holding in Rutherford, hitting net asset value per share by 2.5 pence.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
1 Sep 2022 17:52

TRADING UPDATES: Strong interim results from Johnson Service, Eurocell

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Aug 2022 16:26

TRADING UPDATES: Malvern revenue jumps; Rockwood eyes Main Market

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Aug 2022 11:57

IN BRIEF: Graft Polymer wins first commercial order for GraftBio

Graft Polymer (UK) PLC - London-based company focused on the development and production of polymer modification, biological supplements, and nano-drug delivery systems - Wins first commercial purchase order for its GraftBio division. Order for 50,000 units of its anti-inflammatory supplement, ArtemiC Rescue from MGC Pharmaceuticals PLC. Order worth around USD1 million. Production to start immediately. Delivery expected over the next three months. Chief Executive Victor Volduev says he expects follow-on orders in the coming quarters.

Read more
17 Aug 2022 11:12

MGC shares rise on USD1 million order for ArtemiC

(Alliance News) - MGC Pharmaceuticals Ltd shares were lifted on Wednesday after it announced a USD1 million order for its neutraceutical, ArtemiC.

Read more
15 Aug 2022 17:31

IN BRIEF: MGC Pharma's CannEpil found safe for driving in study

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says clinical study results for its epilepsy treatment, CannEpil, are complete. The study found CannEpil to be safe for post-treatment driving activities. It used a driving simulator to test whether the drug caused somnolence, ie drowsiness, or impairs cognition. It was sponsored by Cannvalate Australia, and conducted by the Centre of Human Psychopharmacology at Swinburne University of Technology, under the Medical Cannabis Research Collaboration.

Read more
5 Aug 2022 14:58

TRADING UPDATES: 4D Pharma warns of wind-up; Star Phoenix files claim

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
29 Jul 2022 19:36

TRADING UPDATES: Walker Crips assets grow; Minoan interim loss narrows

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
28 Jul 2022 20:08

TRADING UPDATES: Scottish American outperforms; Amte picks Dundee

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Jul 2022 21:53

IN BRIEF: MGC Pharmaceuticals quarterly sales "strong"

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says "strong" quarterly sales continue, notes AUD1.6 million, about GBP923,000, in cash receipts during three month period to June 30. In 12-month period, records AUD6.1 million in cash receipts.

Read more
14 Jul 2022 21:44

TRADING UPDATES: Shield closer to Canada approval; Angle plans raise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
8 Jul 2022 14:19

IN BRIEF: MGC Pharmaceuticals wins approval for Covid study, shares up

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Receives approval from South African Health Products Regulatory Authority for a Phase 2b dose finding study of its nanoparticle formulation CimetrA on patients diagnosed with Covid-19.

Read more
6 Jul 2022 20:08

IN BRIEF: MGC Pharmaceuticals launches medical data app ZAM

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says it is set to launch a real-time data collection application, ZAM, for use across the pharmaceutical and health care sectors, in collaboration with software development company, Caba Tech. The app will be available during the third quarter and will enable patients to log their medical history and monitor their medication use. ZAM, through the collection the patient data, will also provide users with a more complete understanding of their health and treatments, it says.

Read more
27 Jun 2022 20:27

IN BRIEF: MGC's CimetrA shows promise beyond Covid applications

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says preliminary results from pre-clinical in vitro study of CimetrA show it could have "wide-ranging application" as anti-inflammatory treatment. This is through the treatment's modulation of the production of pro-inflammatory cytokines. The study was undertaken by Israeli contract research organisation, Science in Action. Results support previous findings from a 2020 study into Covid-19, which showed CimetrA modulates the body's production of cytokines, which can lead to a cytokine storm, a type of severe immune reaction. New results support the potential of CimetrA to have a wider-ranging application as anti-inflammatory treatment, beyond the treatment of Covid-19 symptoms.

Read more
24 Jun 2022 10:13

IN BRIEF: MGC Pharma moves ahead with Covid-19 treatment in US

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Progresses plans to begin US clinical trial for its Covid-19 treatment CimetrA, as MGC and AMC Holdings Inc executives meet with department heads from the University of South Florida. Parties also discuss regulatory approvals for phytocannabinoid medicines CogniCann and CannEpil in the US for early patient access schemes. Says US market access and distribution agreement has been signed with minimum orders of USD24 million over three years, including CimetrA.

Read more
16 Jun 2022 13:43

IN BRIEF: MGC Pharmaceuticals completes research study on brain cancer

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Completes an in-vitro preclinical research study with the National Institute of Biology into the use of cannabinoids to treat brain cancer. The company says the study, undertaken on 30 biopsy samples from 18 patients over a period of three years, sought to determine the optimal formulation for the treatment of Glioblastoma, a form of brain cancer. The study showed that MGC Pharma's proprietary formulations were cytotoxic to Glioblastoma tumour and stem cells, reducing the cells' viability and inducing caspase-dependent cell apoptosis, or cell death.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.